enVVeno Medical (NVNO)
(Delayed Data from NSDQ)
$5.23 USD
-0.07 (-1.32%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $5.22 -0.01 (-0.19%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
NVNO 5.23 -0.07(-1.32%)
Will NVNO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NVNO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVNO
enVVeno (NVNO) Plans to Expedite enVVe Development for CVI
NVNO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for NVNO
enVVeno Medical appoints Sandy Prietto as VP, marketing
enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing
enVVeno provides update on FDA premarket approval application for VenoValve
enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)
enVVeno Medical reports Q2 results